Virus

Norovirus Link to Crohn's Disease May Point to New Therapies

Retrieved on: 
Wednesday, October 5, 2022

Norovirus, a common infection that causes vomiting and diarrhea, is one of several viruses and bacteria thought to trigger disease onset in Crohn's patients, but the field does not know why.

Key Points: 
  • Norovirus, a common infection that causes vomiting and diarrhea, is one of several viruses and bacteria thought to trigger disease onset in Crohn's patients, but the field does not know why.
  • One clue emerged when past studies found that a certain genetic change (mutation) is present in most patients with the condition.
  • This protein adds an extra layer of protection against immune damage, so even those with the mutation can have a healthy gut.
  • However, the researchers also found that norovirus infection blocks T cell secretion of API5 in mice bred to have a rodent form of Crohn's disease, killing gut-lining cells in the process.

Hospitals Set Disinfection Records; LightStrike Germ-Zapping Robots Complete 35 Million Cycles in Healthcare Facilities Worldwide

Retrieved on: 
Wednesday, October 5, 2022

In a milestone achievement, Xenex LightStrike Germ-Zapping Robot customers recently completed 35 million disinfection cycles.

Key Points: 
  • In a milestone achievement, Xenex LightStrike Germ-Zapping Robot customers recently completed 35 million disinfection cycles.
  • View the full release here: https://www.businesswire.com/news/home/20221005005572/en/
    Xenex LightStrike Germ-Zapping Robots are used worldwide to quickly destroy viruses, bacteria and spores that can lurk on high-touch surfaces in healthcare facilities.
  • LightStrike robots, deployed by more than 1,000 healthcare facilities, use IoT (Internet of Things) technology to report utilization to a cloud-based portal.
  • More than 45 peer-reviewed, published studies in scientific journals validate the efficacy of the LightStrike disinfection technology.

KaliVir Immunotherapeutics to Present Data on its Novel Pre-Clinical Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022

Location: Poster Hall, Boston Convention and Exhibition Center, Boston, MA

Key Points: 
  • Location: Poster Hall, Boston Convention and Exhibition Center, Boston, MA
    KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, multi-therapeutic oncolytic viral immunotherapy programs.
  • KaliVir's oncolytic virus candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types.
  • KaliVir has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic vaccinia viruses derived from the VET platform.
  • In addition, Astellas entered into a world-wide exclusive license to develop and commercialize KaliVir's initial lead clinical candidate VET2-L2 oncolytic vaccinia virus.

Antimicrobial Coatings Market worth $7.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, October 5, 2022

Silver-based antimicrobial coatings are widely used in various applications because of there have high efficacy against viruses, bacteria, and other eukaryotic microorganisms.

Key Points: 
  • Silver-based antimicrobial coatings are widely used in various applications because of there have high efficacy against viruses, bacteria, and other eukaryotic microorganisms.
  • Silver-based antimicrobial coatings have proven strong inhibitory properties against bacteria and viruses, such as E.coli, H1N1 influenza, and Listeria.
  • The efficacy of silver-based antimicrobial coatings depends on the size and shape of the silver ion used during manufacturing of coatings.
  • North America is also estimated to be the largest market for Antimicrobial coatings Market during the forecast period.

Antimicrobial Coatings Market worth $7.0 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, October 5, 2022

Silver-based antimicrobial coatings are widely used in various applications because of there have high efficacy against viruses, bacteria, and other eukaryotic microorganisms.

Key Points: 
  • Silver-based antimicrobial coatings are widely used in various applications because of there have high efficacy against viruses, bacteria, and other eukaryotic microorganisms.
  • Silver-based antimicrobial coatings have proven strong inhibitory properties against bacteria and viruses, such as E.coli, H1N1 influenza, and Listeria.
  • The efficacy of silver-based antimicrobial coatings depends on the size and shape of the silver ion used during manufacturing of coatings.
  • North America is also estimated to be the largest market for Antimicrobial coatings Market during the forecast period.

Continuous Glucose Monitoring (CGM) Market to Grow by 13% Annually Through 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022

The "Continuous Glucose Monitoring (CGM) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Glucose Monitoring (CGM) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Continuous Glucose Monitoring (CGM) Market is expected to register a CAGR greater than 13% over the forecast period, 2022-2027.
  • Governments around the world developed programs to educate diabetes patients and health care providers about the usage of continuous glucose monitoring devices.
  • Continuous glucose monitoring has become a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients.

EQS-News: Three disruptive approaches in biotechnology and medicine win the BioRiver Boost! 2022 biotech start-up competition

Retrieved on: 
Wednesday, October 5, 2022

Three disruptive approaches in biotechnology and medicine win the BioRiver Boost!

Key Points: 
  • Three disruptive approaches in biotechnology and medicine win the BioRiver Boost!
  • Three disruptive approaches in biotechnology and medicine win the BioRiver Boost!
  • 2022 biotech start-up competition
    Dsseldorf/Hilden, October 5th, 2022: The winner of this years BioRiver Boost!
  • In its ninth iteration, on September 29, 2022, BioRiver Boost!, selected the three best young European-based companies.

Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Retrieved on: 
Tuesday, October 4, 2022

SEATTLE, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced the initiation of a Phase 1 clinical trial of IVX-A12, a combination bivalent RSV and hMPV VLP vaccine candidate, in older adults.

Key Points: 
  • IVX-A12 is comprised of IVX-121, Icosavaxs RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavaxs hMPV prefusion F protein VLP vaccine candidate.
  • Simpson continued, In older adults, RSV is estimated to cause approximately 177,000 hospitalizations and 14,000 deaths each year in the U.S. alonei, and data support similar morbidity and mortality for hMPV.
  • Icosavax anticipates announcing topline interim results from this Phase 1 trial in mid-2023, with subjects thereafter followed through 12 months after vaccination.
  • Contingent upon a positive outcome from this trial, the company then expects to initiate a Phase 2 trial for IVX-A12 in 2H 2023.

InventHelp Inventor Develops Touchless Way to Sanitize Hands (LJD-126)

Retrieved on: 
Tuesday, October 4, 2022

My design would eliminate the need to continually wipe down door handles, counters and other surfaces using disinfectants."

Key Points: 
  • My design would eliminate the need to continually wipe down door handles, counters and other surfaces using disinfectants."
  • The patent-pending invention provides a touchless way to sanitize hands in public places.
  • The original design was submitted to the Long Island sales office of InventHelp.
  • 20-LJD-126, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Cue Health Applies with FDA for Emergency Use Authorization of its Cue Flu + COVID-19 Molecular Test

Retrieved on: 
Tuesday, October 4, 2022

SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced that on September 30, 2022, it submitted an application with the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its Cue® Flu + COVID-19 Molecular Test for at-home and point-of-care (POC) use.

Key Points: 
  • The new Cue Flu + COVID-19 Molecular Test can simultaneously detect and differentiate between influenza and COVID-19 in approximately 25 minutes, with results delivered digitally to the Cue Health App on the user's mobile device.
  • The Cue Flu + COVID-19 Molecular Test Cartridge uses a lower nasal swab sample and runs on the Cue Reader, which communicates test results digitally to the Cue Health App on a mobile device.
  • Currently, Cue's standalone molecular tests for both flu and COVID-19 are under de novo review with the FDA for full clearance.
  • Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.